Targeting of Antigen Presenting Cells with Immunonanotherapeutics

• US 20100129392A1
• Filed: 04/22/2009
• Published: 05/27/2010
• Est. Priority Date: 10/12/2008
• Status: Active Grant

• Current Assignee: Brigham and Women's Hospital Incorporated, President and Fellows of Harvard College (Harvard Corporation), Massachusetts Institute of Technology
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Farokhzad, Omid C., Langer, Robert, Iannacone, Matteo, von Andrian, Ulrich, Basto, Pamela, Shi, Jinjun, Alexis, Frank, Moseman, Ashley
• Granted Patent: US 8,343,497 B2
• Time in Patent Office: Days
• US Class Current: 424/193.100
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 47/6925 the form being a microcapsule, nanocapsule, microbubble or nanobubble
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.

Claims

1. A composition comprising:

(1) synthetic nanocarriers having at least one surface, wherein a first surface of the synthetic nanocarriers comprises an immunofeature surface; and

(2) a pharmaceutically acceptable excipient.

2. The composition of claim 1, wherein the immunofeature surface comprises a plurality of moieties, and wherein the plurality of moieties are present in a density equal to or greater than the density required to obtain at least 10% of the maximal immobilization observed for a monoclonal antibody (MAb) in an antigen presenting cell (APC) binding assay, provided that, in the APC binding assay, the half maximal binding density for the plurality of moieties is at least twice the half maximal binding density for the MAb.

3. The composition of claim 2, wherein the plurality of moieties are present in a density equal to or greater than the density required to obtain at least 20% of the maximal immobilization observed for a MAb in the APC binding assay.

4. The composition of claim 2, wherein the half maximal binding density for the plurality of moieties is at least four times the half maximal binding density for the MAb.

5. The composition of claim 2, wherein the APC binding assay comprises:

(a) preparing a series of substrates having coatings of a functional moiety at a series of surface coating densities, wherein the functional moiety is capable of binding to dendritic cell (DC) or subcapsular sinus macrophage surface receptors;

(b) exposing the series of substrates to single-cell suspensions of DCs or subcapsular sinus macrophages for a predetermined period of time;

(c) removing non-adhered APCs from the series of substrates, and fixing the adhered APCs to the series of substrates;

(d) quantifying the number of adhered APCs per unit surface area for each substrate in the series of substrates;

(e) plotting the result from (d) against the coating density of the functional moiety;

(f) obtaining a value for the maximal immobilization by determining the maximum number of adhered APCs per unit surface area for the series of substrates; and

(g) obtaining a value for half maximal binding density by determining the surface coating density that provides 50% of the maximum.

6. The composition of claim 2, wherein the MAb is selected from anti-CD1c (BDCA-1) Clone AD5-8E7 and rat anti-mouse CD169, clone 3D6.112, isotype IgG2a.

7. The composition of claim 1, wherein the immunofeature surface comprises a B-cell antigen.

8. The composition of claim 1, wherein the immunofeature surface comprises a plurality of different moieties.

9. The composition of claim 1, wherein the immunofeature surface comprises one or more moieties that are positively charged, negatively charged, or neutral when the one or more moieties are in a buffered, aqueous solution at a pH in the range 7.2-7.4.

10. The composition of claim 1, wherein the surface of the synthetic nanocarriers further comprises a targeting moiety.

11. The composition of claim 1, wherein the synthetic nanocarriers further comprise one or more of an immunostimulatory agent, an immunomodulatory agent, a B cell antigen, and a T cell antigen.

12. The composition of claim 11, wherein the immunostimulatory agent, B cell antigen, or T cell antigen is on:

(i) the immunofeature surface;

(ii) a second surface of the nanocarrier;

or (iii) encapsulated within a core region of the nanocarrier.

13. The composition of claim 1, wherein the diameter of the nanocarriers is greater than 100 nm.

14. The composition of claim 1, wherein the pharmaceutically acceptable excipient is selected from solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, and lubricants.

15. The composition of claim 1, wherein the composition is effective at targeting a subcapsular sinus macrophage.

16. The composition of claim 1, wherein the composition is effective at targeting a dendritic cell.

17. The composition of claim 1, wherein the composition does not substantially activate complement.

18. A method comprising administering a first dose of the composition of claim 1 to a subject.

19. The method of claim 18, further comprising administering a second dose of the composition to the subject after an interval ranging from 1 day to 1 year.

20. The method of claim 19, wherein the interval ranges from 1 day to 1 month.

21. The method of claim 19, wherein the interval ranges from 1 day to 1 week.

22. A method for increasing the uptake of an antigen by a subcapsular sinus macrophage, comprising administering to a subject in need thereof a composition comprising:

(1) a synthetic nanocarrier comprising;

(a) at least one surface, wherein a first surface of the synthetic nanocarrier comprises an immunofeature surface; and

(b) an antigen, wherein the antigen is on;

(i) the immunofeature surface;

(ii) a second surface of the nanocarrier;

or (iii) encapsulated within a core region of the nanocarrier; and

(2) a pharmaceutically acceptable excipient

23. The method of claim 22, wherein the antigen is conjugated to the nanocarrier in a density equal to or greater than the density required to obtain at least 10% of the maximal immobilization observed for a monoclonal antibody (MAb) in an antigen presenting cell binding assay.

24. The method of claim 22, wherein the subcapsular macrophage is a CD169+ macrophage.

25. The method of claim 22, wherein the nanocarrier further comprises an immunostimulatory agent on:

(i) the immunofeature surface;

(ii) a second surface of the nanocarrier;

or (iii) encapsulated within the core region of the nanocarrier.